MOTS-c: difference between revisions
Diff·revision 10 → 11·15:14, 30 Mar 2025
Difference between revision 10 and revision 11 of MOTS-c. 5 lines changed; the page grew by 552 bytes.
| Revision 10 — 12:28, 13 Mar 2025 TirzTaxonomist (talk) add the parent protein and the residue range the fragment spans 2,696 bytes +33 | Revision 11 — 15:14, 30 Mar 2025 EpitalonEoin (talk) split the pharmacology section from the marketing history 3,248 bytes +552 | ||
|---|---|---|---|
| 21 | Detection and quantification are analytically demanding. Short peptides at low circulating concentration require sensitive and specific methods, and reported concentrations differ between studies using different assays — the same caution that applies to any peptide immunoassay. See [[Proglucagon]] for a worked example of the problem.{{r|kim2018}} | 21 | Detection and quantification are analytically demanding. Short peptides at low circulating concentration require sensitive and specific methods, and reported concentrations differ between studies using different assays — the same caution that applies to any peptide immunoassay. See [[Proglucagon]] for a worked example of the problem.{{r|kim2018}} |
| 22 | 22 | ||
| + | 23 | == Reported effects == | |
| + | 24 | In rodents, administration has been reported to improve insulin sensitivity, increase glucose disposal, and attenuate diet-induced obesity, with AMP-activated protein kinase activation the proposed common mechanism.{{r|lee2015}} | |
| + | 25 | ||
| + | 26 | In humans, exercise increases circulating MOTS-c, and lower concentrations have been associated with obesity and insulin resistance in cross-sectional studies. Association of that kind cannot establish direction: lower concentrations may contribute to the phenotype or result from it.{{r|kim2018}} | |
| + | 27 | ||
| 23 | == References == | 28 | == References == |
| 24 | {{reflist}} | 29 | {{reflist}} |